Reply to the Letter to the Editor ‘Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?’ by Y. Sasaki; E. Sato & C. Sakaguchi
| Autor: | J. Tanizaki, K. Nakagawa, H. Hayashi |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Annals of Oncology. 33:1083-1084 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/j.annonc.2022.06.006 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|